Find your next paid study

Kaken PharmaceuticalNCT07285005

A Two-stage Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

The main purpose of this study in participants with PIK3CA-mutated LyM is to assess the change in radiological response and symptom severity upon treatment wit…

Lymphatic Malformations

Novartis PharmaceuticalsNCT05948943

Lymphatic Anomalies Registry for the Assessment of Outcome Data

Lymphatic anomalies are a rare subset of vascular anomalies that are poorly understood. the understanding of the natural history, long-term outcomes, risk fact…

Lymphatic MalformationGeneralized Lymphatic Anomaly (GLA)Central Conducting Lymphatic Anomaly+7 more

Boston Children's HospitalNCT02399527

~$10 – $750

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation

This is a 3-part Phase 2 randomized study evaluating the safety and efficacy of the mutant-selective PI3Kα inhibitor, zovegalisib (RLY-2608), in adults and chi…

Relay Therapeutics, Inc.NCT06789913

A Phase 2a/b Single Arm Open Label Study to Evaluate the Safety and Efficacy of Intracystic Administration of TARA-002 in Participants Between 6 Months to Less Than 18 Years of Age for the Treatment of Macrocystic and Mixed Cystic Lymphatic Malformations

This is a Phase 2a/b single arm open label study to evaluate the safety, reactogenicity, and efficacy of intracystic injection of TARA-002 in participants 6 mo…

Lymphatic Malformation

Protara TherapeuticsNCT05871970

Venous MalformationLymphatic Malformation

Weekly Sirolimus Therapy for the Treatment of Venous and Lymphatic Malformations

In current practice, options for venous and lymphatic malformations remain limited. Recently an oral medication, sirolimus, has been found to benefit patients …